European Journal of Nuclear Medicine

, Volume 8, Issue 1, pp 12–14 | Cite as

Acute effects of nicotinic acid on hepatic transport of 99mTc-PIPIDA

  • Rex B. Shafer
  • Robert G. Knodell
  • Laura N. Stanley
  • Michael K. Elson
Article
Received:
Accepted:

Abstract

Hepatic injury has been associated with nicotinic acid treatment of schizophrenia and hypercholesterolemia. This association was implicated when the liver and biliary tract were not visualized after 99mTc-HIDA in a patient taking 3 g daily of nicotinic acid. We studied hepatic transport of 99mTc-PIPIDA both in vitro in isolated hepatocytes and in vivo in rabbits pretreated with nicotinic acid to further examine this association. Nicotinic acid increased uptake of PIPIDA by isolated hepatocytes and 7 days of nicotinic acid treatment in rabbits produced no abnormalities in hepatic uptake, gallbladder visualization, or biliary excretion of PIPIDA. We conclude that nicotinic acid does not have an inhibitory effect on uptake of biliary imaging agents and actually may be useful in enhancing hepatic imaging in patients with reduced liver function.

Keywords

Public Health Schizophrenia Nuclear Medicine Liver Function Nicotinic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berge KG (1961) Side effects of nicotinic acid in treatment of hypercholesterolemia. Geriatrics 16:416–422Google Scholar
  2. Berge KG, Achor RWP, Christensen NA, Mason HL, Barker NW (1961) Hypercholesterolemia and nicotinic acid: a long-term study. Am J Med 31:24–36Google Scholar
  3. Belle M, Halpern MM (1958) Oral nicotinic acid for hyperlipemia. Am J Cardiol 2:449–452Google Scholar
  4. Hoffer A (1963) Nicotinic acid: an adjunct in the treatment of schizophrenia. Am J Psychiatry 120:171–173Google Scholar
  5. Kety S (1967) Current biochemical approaches to schizophrenia. N Engl J Med 276: 325–331Google Scholar
  6. Kline NS, Barclay GL, Cole JO, Esser AH, Lehmann H, Wittenborn JR (1967) Diphosphopyridinenucleotide (DPN) in the treatment of schizophrenia. JAMA 200: 881–882Google Scholar
  7. Mosher LR (1970) Nicotinic acid side effects and toxicity: A review. Am J Psychiatry 126: 124–130Google Scholar
  8. Osmond H, Hoffer A (1962) Massive niacin treatment of schizophrenia: Review of a 9-year study. Lancet I: 316–319Google Scholar
  9. Pardue WO (1961) Severe liver dysfunction during nicotinic acid therapy. JAMA 175: 137–138Google Scholar
  10. Richards AG, Brighouse R (1981) Nicotinic acid — a cause of failed HIDA scanning. JNM 22: 746–747Google Scholar
  11. Rivin AV (1959) Jaundice occurring during nicotinic acid therapy for hypercholesterolemia. JAMA 170: 2088–2089Google Scholar
  12. Seglen PO (1972) Preparation of rat liver cells: Effect of calcium on enzymatic dispersion of isolated perfused liver. Exp Cell Res 74: 450–454Google Scholar
  13. Winter SL, Boyer JL (1973) Hepatic toxicity from large doses of vitamin B3 (nicotamide). N Engl J Med 289: 1180–1182Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • Rex B. Shafer
    • 1
    • 2
    • 3
  • Robert G. Knodell
    • 1
    • 2
    • 3
  • Laura N. Stanley
    • 1
    • 2
    • 3
  • Michael K. Elson
    • 1
    • 2
    • 3
  1. 1.Nuclear Medicine ServiceVeterans Administration Medical CenterMinneapolisUSA
  2. 2.Department of MedicineVeterans Administration Medical CenterMinneapolisUSA
  3. 3.University of MinnesotaMinneapolisUSA

Personalised recommendations